BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36044839)

  • 1. Arid1a mutation suppresses TGF-β signaling and induces cholangiocarcinoma.
    Guo B; Friedland SC; Alexander W; Myers JA; Wang W; O'Dell MR; Getman M; Whitney-Miller CL; Agostini-Vulaj D; Huber AR; Mello SS; Vertino PM; Land HK; Steiner LA; Hezel AF
    Cell Rep; 2022 Aug; 40(9):111253. PubMed ID: 36044839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice.
    Kasuga A; Semba T; Sato R; Nobusue H; Sugihara E; Takaishi H; Kanai T; Saya H; Arima Y
    Cancer Sci; 2021 May; 112(5):1822-1838. PubMed ID: 33068050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of ARID1A induces a stemness gene ALDH1A1 expression with histone acetylation in the malignant subtype of cholangiocarcinoma.
    Yoshino J; Akiyama Y; Shimada S; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Yamaoka S; Tanabe M; Tanaka S
    Carcinogenesis; 2020 Jul; 41(6):734-742. PubMed ID: 31665232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ARID1A suppresses malignant transformation of human pancreatic cells via mediating senescence-associated miR-503/CDKN2A regulatory axis.
    Li ZY; Zhu SS; Chen XJ; Zhu J; Chen Q; Zhang YQ; Zhang CL; Guo TT; Zhang LM
    Biochem Biophys Res Commun; 2017 Nov; 493(2):1018-1025. PubMed ID: 28942143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of ARID1A Expression Presents a Novel Pathway of Carcinogenesis in Biliary Carcinomas.
    Sasaki M; Nitta T; Sato Y; Nakanuma Y
    Am J Clin Pathol; 2016 Jun; 145(6):815-25. PubMed ID: 27334809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SWI/SNF component
    Wang SC; Nassour I; Xiao S; Zhang S; Luo X; Lee J; Li L; Sun X; Nguyen LH; Chuang JC; Peng L; Daigle S; Shen J; Zhu H
    Gut; 2019 Jul; 68(7):1259-1270. PubMed ID: 30315093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 protects against formation of extrahepatic biliary precancerous lesions in the context of oncogenic Kras.
    Nagao M; Mizukoshi K; Nakayama S; Namikawa M; Hiramatsu Y; Maruno T; Nakanishi Y; Tsuruyama T; Fukuda A; Seno H
    Oncotarget; 2023 Mar; 14():276-279. PubMed ID: 36999984
    [No Abstract]   [Full Text] [Related]  

  • 8. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.
    Xu L; Hausmann M; Dietmaier W; Kellermeier S; Pesch T; Stieber-Gunckel M; Lippert E; Klebl F; Rogler G
    BMC Cancer; 2010 Jun; 10():302. PubMed ID: 20565817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arid1a restrains Kras-dependent changes in acinar cell identity.
    Livshits G; Alonso-Curbelo D; Morris JP; Koche R; Saborowski M; Wilkinson JE; Lowe SW
    Elife; 2018 Jul; 7():. PubMed ID: 30014851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.
    Saha SK; Parachoniak CA; Ghanta KS; Fitamant J; Ross KN; Najem MS; Gurumurthy S; Akbay EA; Sia D; Cornella H; Miltiadous O; Walesky C; Deshpande V; Zhu AX; Hezel AF; Yen KE; Straley KS; Travins J; Popovici-Muller J; Gliser C; Ferrone CR; Apte U; Llovet JM; Wong KK; Ramaswamy S; Bardeesy N
    Nature; 2014 Sep; 513(7516):110-4. PubMed ID: 25043045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational spectrum and precision oncology for biliary tract carcinoma.
    Lin J; Cao Y; Yang X; Li G; Shi Y; Wang D; Long J; Song Y; Mao J; Xie F; Bai Y; Zhang L; Yang X; Wan X; Wang A; Guan M; Zhao L; Hu K; Pan J; Huo L; Lu X; Mao Y; Sang X; Zhang H; Wang K; Wang X; Zhao H
    Theranostics; 2021; 11(10):4585-4598. PubMed ID: 33754015
    [No Abstract]   [Full Text] [Related]  

  • 12. Autophagy may occur at an early stage of cholangiocarcinogenesis via biliary intraepithelial neoplasia.
    Sasaki M; Nitta T; Sato Y; Nakanuma Y
    Hum Pathol; 2015 Feb; 46(2):202-9. PubMed ID: 25466963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between KRAS gene mutations and linicopathological features of patients with intrahepatic cholangiocarcinoma.
    Wang J; Xu MX; Wang LQ; Li HY; Wang ZL; Li LJ
    J Biol Regul Homeost Agents; 2019; 33(5):1551-1557. PubMed ID: 31635679
    [No Abstract]   [Full Text] [Related]  

  • 14. Mutation analysis and copy number changes of KRAS and BRAF genes in Taiwanese cases of biliary tract cholangiocarcinoma.
    Huang WC; Tsai CC; Chan CC
    J Formos Med Assoc; 2017 Jun; 116(6):464-468. PubMed ID: 27745798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways.
    Schlitter AM; Born D; Bettstetter M; Specht K; Kim-Fuchs C; Riener MO; Jeliazkova P; Sipos B; Siveke JT; Terris B; Zen Y; Schuster T; Höfler H; Perren A; Klöppel G; Esposito I
    Mod Pathol; 2014 Jan; 27(1):73-86. PubMed ID: 23828315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low expression of ARID1A correlates with poor prognosis in intrahepatic cholangiocarcinoma.
    Yang SZ; Wang AQ; Du J; Wang JT; Yu WW; Liu Q; Wu YF; Chen SG
    World J Gastroenterol; 2016 Jul; 22(25):5814-21. PubMed ID: 27433094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells.
    Sen M; Wang X; Hamdan FH; Rapp J; Eggert J; Kosinsky RL; Wegwitz F; Kutschat AP; Younesi FS; Gaedcke J; Grade M; Hessmann E; Papantonis A; Strӧbel P; Johnsen SA
    Clin Epigenetics; 2019 Jun; 11(1):92. PubMed ID: 31217031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer.
    Lee SH; Cheon J; Lee S; Kang B; Kim C; Shim HS; Park YN; Jung S; Choi SH; Choi HJ; Lee CK; Chon HJ
    Cancer Res Treat; 2023 Oct; 55(4):1291-1302. PubMed ID: 37139666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways.
    Kongpetch S; Jusakul A; Ong CK; Lim WK; Rozen SG; Tan P; Teh BT
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):233-44. PubMed ID: 25966424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands.
    Nakagawa H; Suzuki N; Hirata Y; Hikiba Y; Hayakawa Y; Kinoshita H; Ihara S; Uchino K; Nishikawa Y; Ijichi H; Otsuka M; Arita J; Sakamoto Y; Hasegawa K; Kokudo N; Tateishi K; Koike K
    Proc Natl Acad Sci U S A; 2017 May; 114(19):E3806-E3815. PubMed ID: 28439013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.